Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma

被引：0
作者：
Van Hulst, Glenn [1 ]
Jorssen, Joseph [1 ]
Jacobs, Nathalie [1 ]
Henket, Monique [2 ]
Louis, Renaud [2 ]
Schleich, Florence [3 ]
Bureau, Fabrice [1 ]
Desmet, Christophe [1 ]
机构：
[1] Univ Liege, Lab Cellular & Mol Immunol, Liege, Belgium
[2] CHU Liege, Pneumol, Liege, Belgium
[3] Univ Liege, Dept Pulm Med, Liege, Belgium
来源：
EUROPEAN RESPIRATORY JOURNAL | 2021年 / 58卷
关键词：
Asthma;
D O I：
10.1183/13993003.congress-2021.PA890
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA890
引用
收藏
页数：2
相关论文
共 23 条
  • [1] Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
    Menzella, Francesco
    Lusuardi, Mirco
    Galeone, Carla
    Taddei, Sofia
    Zucchi, Luigi
    JOURNAL OF ASTHMA AND ALLERGY, 2015, 8 : 105 - 114
  • [2] Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy
    Kroes, Johannes A.
    Zielhuis, Sybrand W. J.
    De Jong, Kim
    Zielhuis, Sander W.
    Van Roon, Eric N.
    Bel, Elisabeth H. D.
    Ten Brinke, Anneke
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [3] Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma
    Pavord, Ian
    Korn, Stephanie
    Howarth, Peter
    Bleecker, Eugene
    Buhl, Roland
    Keene, Oliver
    Ortega, Hector
    Pascal, Pascal Chanez
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [4] Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy
    Panagiotou, Marios
    Koulouris, Nikolaos
    Koutsoukou, Antonia
    Tsami, Maria
    Syrigou, Ekaterini
    Rovina, Nikoletta
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [5] Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab
    Suzaki, Isao
    Kimura, Yurika
    Tanaka, Akihiko
    Hirano, Kojiro
    Ishibashi, Atsushi
    Mizuyoshi, Tomomi
    Ando, Izumi
    Kitajima, Tatsuya
    Watanabe, So
    Hinohira, Yasuyuki
    Kobayashi, Hitome
    AURIS NASUS LARYNX, 2019, 46 (01) : 141 - 146
  • [6] Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma
    Przybyszowski, Marek
    Gross-Sondej, Iwona
    Zarychta, Jacek
    Bazan-Socha, Stanislawa
    Bochenek, Grazyna
    Soja, Jerzy
    Sladek, Krzysztof
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [7] LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils
    Brusselle, Guy
    Germinaro, Matthew
    Eid, Sherrine
    Zangrilli, James
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [8] Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma
    Kuprys-Lipinska, Izabela
    Majak, Pawel
    Tyrak, Katarzyna Ewa
    Molinska, Joanna
    Kurmanowska, Zofia
    Zal, Aleksandra
    Krzyzanowski, Damian
    Jonakowski, Mateusz
    Mastalerz, Lucyna
    Kuna, Piotr
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [9] Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma
    Eger, Katrien A. B.
    Kroes, Johannes A.
    Ten Brinke, Anneke
    Sont, Jacob K.
    Bel, Elisabeth H.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [10] Serum Amphiregulin expression in severe asthma patients treated with anti-IL-5 therapy
    Bagnasco, Diego
    Riccio, Anna Maria
    De Ferrari, Laura
    Massolo, Alessandro
    Caminati, Marco
    Manfredi, Andrea
    Senna, Gianenrico
    Passalacqua, Giovanni
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
123